Megan A. Waldrop

1.2k total citations
48 papers, 677 citations indexed

About

Megan A. Waldrop is a scholar working on Molecular Biology, Genetics and Surgery. According to data from OpenAlex, Megan A. Waldrop has authored 48 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 24 papers in Genetics and 15 papers in Surgery. Recurrent topics in Megan A. Waldrop's work include Neurogenetic and Muscular Disorders Research (23 papers), Muscle Physiology and Disorders (19 papers) and RNA modifications and cancer (13 papers). Megan A. Waldrop is often cited by papers focused on Neurogenetic and Muscular Disorders Research (23 papers), Muscle Physiology and Disorders (19 papers) and RNA modifications and cancer (13 papers). Megan A. Waldrop collaborates with scholars based in United States, France and Italy. Megan A. Waldrop's co-authors include Kevin M. Flanigan, Stephen J. Kolb, Anne M. Connolly, Steven Chessler, Arthur T. Suckow, Jerry R. Mendell, Chang‐Yong Tsao, M. Iammarino, Robert B. Weiss and Davide Comoletti and has published in prestigious journals such as Neurology, PEDIATRICS and Annals of Neurology.

In The Last Decade

Megan A. Waldrop

42 papers receiving 659 citations

Peers

Countries citing papers authored by Megan A. Waldrop

Since Specialization

Citations

This map shows the geographic impact of Megan A. Waldrop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Megan A. Waldrop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Megan A. Waldrop more than expected).

Fields of papers citing papers by Megan A. Waldrop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Megan A. Waldrop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Megan A. Waldrop. The network helps show where Megan A. Waldrop may publish in the future.

Co-authorship network of co-authors of Megan A. Waldrop

This figure shows the co-authorship network connecting the top 25 collaborators of Megan A. Waldrop. A scholar is included among the top collaborators of Megan A. Waldrop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Megan A. Waldrop. Megan A. Waldrop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of Two Questionnaires for Sleep‐Related Symptoms in Pediatric and Adult Patients With Myotonic Dystrophy Type 1 2025 ·Muscle & Nerve ·(unknown), (unknown), (unknown), Grace Paul, Megan A. Waldrop	1
2	Transitioning From Nusinersen to Risdiplam for Spinal Muscular Atrophy in Clinical Practice: A Single‐Center Experience 2025 ·Muscle & Nerve ·Can Ebru Bekircan‐Kurt, Shoba Subramanian, (unknown), (unknown), M. Iammarino, Natalie F. Reash, (unknown), Chang‐Yong Tsao, Garey Noritz, Courtney Gushue, Kavitha Kotha, Grace Paul, Richard Shell, Lindsay N. Alfano, Linda Lowes, Anne M. Connolly, Megan A. Waldrop	3
3	Long-Term Follow-Up Cares and Check Initiative: A Program to Advance Long-Term Follow-Up in Newborns Identified with a Disease through Newborn Screening 2024 ·International Journal of Neonatal Screening ·(unknown), Kee Chan, Jennifer Taylor, Bo Hoon Lee, Emma Ciafaloni, Jennifer M. Kwon, Megan A. Waldrop, Russell J. Butterfield, (unknown), Aravindhan Veerapandiyan, (unknown), Julie Parsons, (unknown), Amy Brower	0
4	Spinal Muscular Atrophy Update in Best Practices 2024 ·Neurology Clinical Practice ·Mary Schroth, J. Deans, Kapil Arya, Diana Castro, Darryl C. De Vivo, (unknown), (unknown), Nancy L. Kuntz, (unknown), (unknown), Mariacristina Scoto, Thomas Sejersen, Laurent Servais, (unknown), Megan A. Waldrop, Juan F. Vázquez‐Costa	9
5	Clinical decision making around commercial use of gene and genetic therapies for spinal muscular atrophy 2024 ·Neurotherapeutics ·Megan A. Waldrop	0
6	Increase in Full-Length Dystrophin by Exon Skipping in Duchenne Muscular Dystrophy Patients with Single Exon Duplications: An Open-label Study 2024 ·Journal of Neuromuscular Diseases ·Stefan Nicolau, Jyoti Malhotra, Maryann Kaler, (unknown), M. Iammarino, Natalie F. Reash, (unknown), Saranga Wijeratne, Benjamin Kelly, Peter White, Linda Lowes, Megan A. Waldrop, Kevin M. Flanigan	5
7	The Early Care (0–3 Years) In Duchenne Muscular Dystrophy Meeting Report 2024 ·Journal of Neuromuscular Diseases ·(unknown), Susan Apkon, Kiera N. Berggren, (unknown), Emma Ciafaloni, Anne M. Connolly, Annie Kennedy, Nancy L. Kuntz, Katherine D. Mathews, (unknown), Richard B. Parad, Mena Scavina, Rebecca J. Scharf, Megan A. Waldrop	2
8	Parental Experiences with Newborn Screening and Gene Replacement Therapy for Spinal Muscular Atrophy 2023 ·Journal of Neuromuscular Diseases ·(unknown), Anne M. Connolly, Kathryn Vannatta, (unknown), (unknown), (unknown), Patricia G. Parker, (unknown), Megan A. Waldrop	3
9	A genome-wide association analysis of loss of ambulation in dystrophinopathy patients suggests multiple candidate modifiers of disease severity 2023 ·European Journal of Human Genetics ·Kevin M. Flanigan, Megan A. Waldrop, Paul T. Martin, (unknown), Diane M. Dunn, Lindsay N. Alfano, (unknown), Melissa Moore‐Clingenpeel, (unknown), (unknown), Robert B. Weiss, Veronica J. Vieland	4
10	A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2 2022 ·Molecular Therapy — Methods & Clinical Development ·Kevin M. Flanigan, (unknown), (unknown), M. Iammarino, (unknown), Federica Rinaldi, Louis G. Chicoine, (unknown), John P. Cheatham, John P. Cheatham, Brian A. Boe, Megan A. Waldrop, (unknown), (unknown), Paul T. Martin	16
11	Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping 2021 ·Human Gene Therapy ·Liubov V. Gushchina, (unknown), (unknown), (unknown), (unknown), Hemantkumar Chavan, (unknown), (unknown), Megan A. Waldrop, Nicolas Wein, Kevin M. Flanigan	27
12	Spinal Muscular Atrophy 2021 ·Seminars in Pediatric Neurology ·Stefan Nicolau, Megan A. Waldrop, Anne M. Connolly, Jerry R. Mendell	32
13	Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests 2020 ·Pediatric Neurology ·N. Miller, Lindsay N. Alfano, M. Iammarino, Anne M. Connolly, Melissa Moore‐Clingenpeel, (unknown), Chang‐Yong Tsao, Megan A. Waldrop, Kevin M. Flanigan, Jerry R. Mendell, Linda Lowes	18
14	Spinal Muscular Atrophy in the Treatment Era 2020 ·Neurologic Clinics ·Megan A. Waldrop, Bakri Elsheikh	16
15	Current Treatment Options in Neurology—SMA Therapeutics 2019 ·Current Treatment Options in Neurology ·Megan A. Waldrop, Stephen J. Kolb	47
16	In-frame de novo mutation in BICD2 in two patients with muscular atrophy and arthrogryposis 2018 ·Molecular Case Studies ·Daniel C. Koboldt, (unknown), Megan A. Waldrop, Benjamin Kelly, Theresa Mihalic Mosher, Heather M. McLaughlin, (unknown), Jonathan L. Slaughter, Kevin M. Flanigan, Kim L. McBride, Lakshmi Mehta, Richard K. Wilson, Peter White	13
17	Clinicopathologic Conference: A Newborn With Hypotonia, Cleft Palate, Micrognathia, and Bilateral Club Feet 2017 ·Pediatric Neurology ·Megan A. Waldrop, Daniel R. Boué, Emily Sites, Kevin M. Flanigan, Richard Shell	6
18	Low-level dystrophin expression attenuating the dystrophinopathy phenotype 2017 ·Neuromuscular Disorders ·Megan A. Waldrop, (unknown), (unknown), Diane E. Frank, Robert B. Weiss, Kevin M. Flanigan	21
19	Intranasal delivery of mouse [D‐Leu‐4]‐OB3, a synthetic peptide amide with leptin‐like activity, improves energy balance, glycaemic control, insulin sensitivity and bone formation in leptin‐resistant C57BLK/6‐m db/db mice 2010 ·Diabetes Obesity and Metabolism ·Megan A. Waldrop, Matthew C. Leinung, (unknown), Patricia Grasso	17
20	Release of Glutamate Decarboxylase-65 into the Circulation by Injured Pancreatic Islet β-Cells 2007 ·Endocrinology ·Megan A. Waldrop, Arthur T. Suckow, Santica M. Marcovina, Steven Chessler	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact